{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:40:29Z","timestamp":1767966029590,"version":"3.49.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite several reports and small case series on the disease course of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI), including X-linked agammaglobulinemia (XLA), this topic remains incompletely described. Here we present the case of a 38-year-old unvaccinated man with XLA, who acquired SARS-CoV-2 infection and experienced a protracted disease course with 47 days of SARS-CoV-2 positivity, critical COVID-19 with respiratory insufficiency necessitating intensive care and ventilatory support, and prompting repeated intensified treatments with remdesivir, dexamethasone, and monoclonal antibodies to eventually control infection. We describe the disease course and treatment and review the current literature on COVID-19 susceptibility and evidence for vaccine efficacy in patients with XLA.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1057065","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:24:55Z","timestamp":1669289095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case report: Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Bruton\u2019s agammaglobulinemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Nina","family":"Rise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toke","family":"Touborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ditte Helene","family":"Lundsted","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dalager-Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trine H.","family":"Mogensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2017.07.008","article-title":"X-Linked agammaglobulinaemia: Outcomes in the modern era","volume":"183","author":"Shillitoe","year":"2017","journal-title":"Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2002.5241","article-title":"Clinical, immunological, and molecular analysis in a Large cohort of patients with X-linked agammaglobulinemia: An Italian multicenter study","volume":"104","author":"Plebani","year":"2002","journal-title":"Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11050632","article-title":"Elevated rates of ventilator-associated pneumonia and COVID-19 associated pulmonary aspergillosis in critically ill patients with SARS-CoV2 infection in the second wave: A retrospective chart review","volume":"11","author":"Boyd","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11040462","article-title":"Comparative evaluation of six SARS-CoV-2 real-time RT-PCR diagnostic approaches shows substantial genomic variant-dependent intra- and inter-test variability, poor interchangeability of cycle threshold and complementary turn-around times","volume":"11","author":"Kogoj","year":"2022","journal-title":"Pathogens"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00120-3","article-title":"Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients","volume":"3","author":"Destras","year":"2022","journal-title":"Lancet Microbe"},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12941-021-00491-2","article-title":"Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy","volume":"20","author":"Taha","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: An international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A possible role for b cells in COVID-19? lesson from patients with agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd0110","article-title":"Inhibition of bruton tyrosine kinase in patients with severe COVID-19","volume":"5","author":"Roschewski","year":"2020","journal-title":"Sci Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Horby","year":"2021","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-00983-y","article-title":"A patient with X-linked agammaglobulinemia and COVID-19 infection treated with remdesivir and convalescent plasma","volume":"41","author":"Iaboni","year":"2021","journal-title":"J Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.13840","article-title":"Atypical course of COVID-19 in patient with bruton agammaglobulinemia","volume":"14","author":"Milo\u0161evi\u0107","year":"2020","journal-title":"J Infect Dev Ctries"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","volume":"31","author":"Soresina","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.929447","article-title":"The clinical course of COVID-19 pneumonia in a 19-Year-Old man on intravenous immunoglobulin replacement therapy for X-linked agammaglobulinemia","volume":"22","author":"Almontasheri","year":"2021","journal-title":"Am J Case Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000792","article-title":"COVID-19 and X-linked agammaglobulinemia (XLA) \u2013 insights from a monogenic antibody deficiency","volume":"21","author":"Ponsford","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30172-5","article-title":"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis","volume":"2","author":"Cevik","year":"2021","journal-title":"Lancet Microbe"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10875-022-01264-y","article-title":"The impact of SARS-CoV-2 infection in patients with inborn errors of immunity: the experience of the Italian primary immunodeficiencies network (IPINet)","volume":"42","author":"Giardino","year":"2022","journal-title":"J Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jaci.2021.10.031","article-title":"Treatment of chronic or relapsing COVID-19 in immunodeficiency","volume":"149","author":"Brown","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for b-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1152\/physiol.00016.2022","article-title":"COVID-19 and inborn errors of immunity","volume":"37","author":"Delmonte","year":"2022","journal-title":"Physiol (Bethesda)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.04.002","article-title":"Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity","volume":"149","author":"van Leeuwen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000514193","article-title":"SARS-CoV-2-Associated T-cell responses in the presence of humoral immunodeficiency","volume":"182","author":"Gupta","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10875-022-01256-y","article-title":"SARS-CoV-2-Specific and functional cytotoxic CD8 cells in primary antibody deficiency: Natural infection and response to vaccine","volume":"42","author":"Gupta","year":"2022","journal-title":"J Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jaci.2021.11.022","article-title":"Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional b-cell defects","volume":"149","author":"Pham","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1057065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:24:57Z","timestamp":1669289097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1057065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2022.1057065"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1057065","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"article-number":"1057065"}}